TG THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
Mailing Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
Phone
(212) 554-4484
Fiscal Year End
1231
EIN
363898269
Financial Overview
FY2025
$648.02M
Stockholders' Equity
$179.89M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 10-K Annual financial report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
| 8-K Current report of material events | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | November 25, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 10, 2025 | View on SEC |
Annual Reports
10-K
February 27, 2026
- Briumvi's successful commercial launch generated $155 million in net product sales in its first full year, exceeding initial analyst expectations.
- The company secured favorable reimbursement coverage and emerging positive real-world data for Briumvi, improving patient access and confidence.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.